Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals faces new scrutiny: a Kahn Swick & Foti probe into a potential sale and Glazer Capital’s fresh stake raise the stakes for its oncology pipeline.

Day One Biopharmaceuticals Inc. navigates the biotech landscape amidst industry developments, leveraging advancements in cancer treatment and quality control to enhance its research and development capabilities.